Introduction
A Harvard-led study has raised concerns about Semaglutide vision loss. The study shows that people prescribed Semaglutide sold under the brand names Ozempic and Wegovy may face a higher risk of developing a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). NAION can cause sudden and often irreversible vision loss.
Mass Eye and Ear-led is the first to discover that people prescribed semaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a form of blindness due to optic nerve disease known as non-arteritic anterior ischemic optic neuropathy (NAION).
Background
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, originally developed to help people with type 2 diabetes regulate blood sugar. In recent years, it has also become widely prescribed for weight loss under the brand name Wegovy. Its rapid rise in popularity—sometimes described as a “weight-loss revolution”—has placed millions of new patients on the drug in a relatively short time.
This surge in use has also led researchers and clinicians to watch closely for emerging side effects that may not have been obvious in earlier clinical trials. While Semaglutide is generally considered safe and effective, any widely prescribed medication can reveal new risks when taken by a larger and more diverse population over time.
The specific interest in eye health came from an unusual clinical observation. In 2023, neuro-ophthalmologists at Mass Eye and Ear noticed a surprising cluster: three patients in one week presented with a rare vision condition called non-arteritic anterior ischemic optic neuropathy (NAION)—and all three were taking semaglutide.
NAION occurs when blood flow to the optic nerve is disrupted, leading to sudden, painless, and often irreversible vision loss. It is considered the second most common cause of optic nerve blindness after glaucoma. However, NAION is still rare in the general population, typically affecting around 10 in 100,000 people each year.
This unusual cluster of cases prompted the researchers to ask: Could there be a link between semaglutide and NAION?
To answer this, the team conducted a retrospective analysis of more than 17,000 patient records spanning six years, comparing those who had been prescribed semaglutide with those on other diabetes and weight-loss medications. The goal was to determine whether the apparent pattern was coincidental—or a real safety signal.
What is Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)?
Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common cause of sudden optic nerve damage in people over age 50. Even though it occurs fairly often, doctors still do not fully understand why it develops, and there is no proven treatment.
Because other serious eye and health problems can look similar to NAION, a careful medical history, eye exam, and sometimes additional tests are very important. These steps help rule out conditions that could threaten sight or even life.
Risk Factors for NAION
Several health and eye conditions can increase the risk of NAION:
- General health risks: Diabetes, high blood pressure, high cholesterol, and smoking are the most common. These conditions affect blood vessels, which play a role in the health of the optic nerve.
- Medications: Some drugs, like erectile-dysfunction medicines (Viagra, Cialis, Levitra), have been linked to Semaglutide vision loss, NAION, possibly because they affect blood flow to the eye.
- Younger patients: In people under 50, blood-clotting problems or an inherited tendency for abnormal clotting may be involved, though often no clear cause is found.
- Eye structure: People with a small, crowded optic nerve (sometimes called a “disc at risk”) are more likely to develop NAION. In younger people, calcium deposits in the optic nerve (called optic disc drusen) can also raise risk.
- Eye surgery: Rarely, NAION has been reported after eye operations such as cataract surgery or LASIK, possibly due to short-term changes in eye pressure during surgery.
Symptoms of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- Sudden, painless vision loss in one eye (the most common sign).
- In rare cases, both eyes can be affected, especially if there are big changes in blood pressure during surgery, dialysis, or heavy blood loss.
- Mild eye discomfort or headache may happen in about 1 in 10 patients, but pain is not typical.
What Eye Doctors See on examination
When examining the eye, doctors may notice:
- https://www.aao.org/eyenet/article/naion-diagnosis-and-managementSwelling of the optic nerve.
- Small bleeding spots near the nerve.
- Narrowing blood vessels around the optic disc.
- The unaffected eye often shows a “disc at risk,” which makes it more vulnerable in the future.
Vision Changes
Vision loss in NAION can range from mild to severe, but total blindness is rare. Many people keep some useful vision: about half still see better than 20/64, and two-thirds better than 20/200.
Color vision can also be reduced, usually in line with the degree of vision loss. The most typical pattern of vision loss is missing part of the lower half of what you see (an “altitudinal” defect).
Understanding Diabetes: Causes, Types, Symptoms, and Complications
Diabetes is a chronic health condition that affects how the body processes blood sugar (glucose), which is the main source of energy for cells. Normally, the hormone insulin, produced by the pancreas, helps glucose move from the bloodstream into the cells. In diabetes, either the body does not produce enough insulin, or it cannot use insulin effectively. This leads to elevated blood sugar levels, which over time can damage organs, nerves, and blood vessels.
Types of Diabetes
There are several types of diabetes. The most common ones include Type 1 Diabetes, Type 2 Diabetes, Prediabetes, Gestational diabetes
- Type 1 Diabetes
- An autoimmune condition where the body’s immune system mistakenly attacks insulin-producing cells in the pancreas.
- Usually diagnosed in children, teens, or young adults, though it can occur at any age.
- People with type 1 diabetes must take insulin daily to survive.
- Type 2 Diabetes
- The most common form, accounting for about 90–95% of cases.
- In this type, the body becomes resistant to insulin or does not make enough of it.
- Risk factors include obesity, poor diet, physical inactivity, age, family history, and certain ethnic backgrounds.
- It can sometimes be managed through lifestyle changes, though many patients also require oral medications or insulin therapy.
- Prediabetes: This type is the stage before Type 2 diabetes. Your blood glucose levels are higher than normal but not high enough to be officially diagnosed with Type 2 diabetes.
- Gestational Diabetes
- Develops during pregnancy when hormones interfere with insulin function.
- Usually resolves after childbirth, but it increases the mother’s risk of developing type 2 diabetes later in life.
Symptoms of Diabetes
Common symptoms include:
- Frequent urination
- Excessive thirst and hunger
- Unexplained weight loss (especially in type 1)
- Fatigue
- Blurred vision
- Slow-healing wounds
- Tingling or numbness in hands and feet
Because symptoms can be mild or develop gradually, many people with type 2 diabetes may not realize they have it until complications arise.
Complications of Diabetes
If left uncontrolled, diabetes can lead to serious health problems:
- Cardiovascular disease: Diabetes increases cardiovascular heart disease risk, Higher risk of heart attack, stroke, and hypertension.
- Neuropathy: Nerve damage causing pain, tingling, or numbness.
- Kidney disease: Diabetes is a leading cause of chronic kidney failure.
- Eye disease: Retinopathy can lead to blindness.
- Foot problems: Poor circulation and nerve damage increase the risk of infections and amputations.
Study Design and Methods
The research linking semaglutide (Ozempic and Wegovy) to a higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) was conducted as a retrospective cohort study by investigators at Mass Eye and Ear, a teaching hospital of Harvard Medical School.
The study was prompted by a clinical observation: in the span of one week, three patients arrived at the neuro-ophthalmology clinic with sudden vision loss from NAION, and all three were taking semaglutide. This unusual cluster raised questions about a possible connection between the semaglutide and optic nerve disease.
To explore the link between semaglutide and vision loss, the researchers reviewed electronic health records spanning six years. The analysis included over 17,000 patients, divided into two primary groups: those who had been prescribed semaglutide for type 2 diabetes or obesity, and those prescribed alternative treatments for these conditions.
The team compared the incidence of NAION between the groups, adjusting for potential confounding factors such as age, sex, cardiovascular health, and other known risk factors for optic nerve damage.
Results showed a significantly higher incidence of NAION in the semaglutide group: more than four times greater in patients with diabetes and over seven times greater in patients with obesity compared to individuals on other medications.
It is important to note that the study design was observational rather than experimental. This means it identified an association but could not establish direct causation. Limitations included reliance on prescription records (which do not confirm adherence), a predominantly white patient sample, and the relatively small number of NAION cases overall, given the condition’s rarity.
Despite these constraints, the design provided strong enough evidence to highlight a potential safety signal, prompting international discussion and further large-scale studies on the link between semaglutide and optic nerve health.
Key Findings
- Among patients with type 2 diabetes, those on semaglutide were over 4× more likely to develop NAION than patients on other diabetes drugs.
- Among patients with overweight or obesity, semaglutide users were over 7× more likely to develop Semaglutide linked vision loss “NAION” compared to those on different weight-loss medications.
- While the findings are striking, the study was observational, it shows an association but not direct proof of causation.
Expert Commentary on Semaglutide Linked Vison Loss
Lead researcher Dr. Joseph Rizzo, a neuro-ophthalmologist at Mass Eye and Ear, emphasized caution:
“Semaglutide vision loss is an important finding, but it’s still early. Our results highlight the need for awareness and further investigation—not immediate alarm. Patients should not stop their medication without consulting their doctors.”
Independent experts have echoed that while the risk appears real, it is still considered very rare relative to the millions of people who benefit from semaglutide.
Implications of findings
- For Patients: Anyone using Ozempic or Wegovy should stay alert for sudden changes in vision, as these could signal potential Semaglutide vision loss. Immediate medical evaluation is essential if symptoms appear.
- For Physicians: These findings suggest the need for more careful monitoring of patients who may already be at risk for optic nerve problems, including those with conditions like glaucoma.
- For Public Health: Major regulatory agencies—such as the European Medicines Agency and the World Health Organization—now acknowledge NAION as a very rare side effect linked to semaglutide and have updated product labeling to reflect the risk of Semaglutide vision loss.
Cautions & Limitations
- The study population was largely white, limiting generalizability.
- It is unclear whether patients consistently took their prescriptions.
- NAION is already rare (around 10 per 100,000 people), so overall risk remains low.
Follow-up studies including one involving 37 million patients worldwide in 2025 suggested the risk increase is much smaller than first reported, though still detectable.
Seek Professional Guide
Patients currently using semaglutide should not discontinue their medication without medical guidance. Instead, they should:
- Discuss these Semaglutide vision loss findings with their healthcare provider.
- Report any sudden vision changes immediately.
- Weigh the benefits of semaglutide such as improved diabetes control and weight loss against the rare but serious risk of NAION.
Conclusion
The Mass Eye and Ear study provides the first clear indication of a potential connection between Semaglutide vision loss and sudden NAION, drawing global attention to these emerging safety concerns. Although more research is underway, the findings highlight the need for close monitoring and open communication between patients and healthcare providers. Semaglutide remains an effective treatment, but this rare yet significant risk is one the medical community continues to evaluate carefully.
SOURCES
- Mass Eye and Ear Press Release (2024, July 3). Popular Prescription Weight Loss Drugs Linked to Uncommon Blinding Condition. https://masseyeandear.org/news/press-releases/2024/07/prescription-weight-loss-drugs-linked-to-blinding-condition
- JAMA Ophthalmology (2024, July 3). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Ophthalmol 2024;142;(8):732-739. doi:10.1001/jamaophthalmol.2024.2296 https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255#google_vignette
- American Academy of Ophthalmology. (2022, Aug 1). NAION: Diagnosis and Management.https://www.aao.org/eyenet/article/naion-diagnosis-and-management
- The Guardian Coverage. (2024, Jul 3). Weight-loss jabs may be linked to condition that can cause blindness, study finds. https://www.theguardian.com/science/article/2024/jul/03/study-possible-link-weight-loss-jabs-wegovy-ozempic-and-naion-condition-blindness
- WHO Safety Update (2025, June 27). The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION)
- Cleveland Clinic. (2023, Feb. 17). Diabetes. https://my.clevelandclinic.org/health/diseases/7104-diabetes
